



CASE TX/4-32304A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV83996104545
Express Mail Label Number

November 7, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
PRESCOTT ET AL.

Art Unit: 1614
Examiner: Weddington,
Kevin E

INTERNATIONAL APPLICATION NO: PCT/EP03/00153

FILED: 9 JANUARY 2003

U.S. APPLICATION NO: 10/501,210

35 USC §371 DATE: 9 JULY 2004

FOR: DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND
TREATMENT OF VASCULAR DISEASES COMPRISING
RAPAMYCIN AND DERIVATIVES THEREOF

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed October 22, 2004. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

11/07/2007 CNGB1 00000000 190134 10501210
01 FC:1006 100.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Leslie Fischer', is written over a horizontal line.

Leslie Fischer
Attorney for Applicants
Reg. No. 58,393

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-9308

Date: Nov 7/07



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV83996104545
Express Mail Label NumberNovember 7, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

PRESCOTT ET AL.

Examiner: Weddington, Kevin E

APPLICATION NO: 10/501,210

FILED: JULY 9, 2004

FOR: DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND
TREATMENT OF VASCULAR DISEASES COMPRISING
RAPAMYCIN AND DERIVATIVES THEREOFCommissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Leslie Fischer
Attorney for Applicants
Reg. No. 58,393Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-9308
Date: Nov. 7/2007